Greenwich has been working on its GP2 immunotherapy to prevent recurrences of breast cancer in patients who have previously undergone surgery. A phase 2b trial showed evidence of greater disease-free survival rates for those taking GP2 in combination with other drugs compared to patients taking only the other drugs. Indeed, the trial involving 138 patients showed no recurrences at all for the GP2 group.
Armed with these results, Greenwich is now looking to find clinical trial partners to move forward with a phase 3 trial. The move higher for the stock has been a big win for investors in Greenwich's IPO, which happened less than three months ago.
Market Data 
Markets 
AI
